GlassScriptPhysician profile
Shilpi Gupta
NPI 1508009366
$7,204.38
in general payments reported to CMS, 2019-2025
50 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $51.04 · 2021: $267 · 2022: $1,566 · 2023: $1,493 · 2024: $1,792 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,852 · Education: $4.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,852.37 |
| Education | $4.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $969.97 | 2019-2025 | Enhertu, Vanflyta, Datroway |
| Novartis Pharmaceuticals Corporation | $887.03 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $559.99 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $454.72 | 2021-2025 | Lynparza, Tagrisso, Enhertu |
| Pfizer INC. | $446.53 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $411.42 | 2019-2025 | Opdivo |
| Amgen INC. | $372.44 | 2019-2023 | Lumakras, Xgeva, Vectibix |
| Mirati Therapeutics, INC. | $276.57 | 2023-2024 | Krazati |
| Glaxosmithkline, LLC. | $262.89 | 2019-2025 | Jemperli, Zejula, Ojjaara |
| Eisai INC. | $258.29 | 2021-2025 | |
| Seagen INC. | $235.13 | 2021-2023 | Tukysa |
| Janssen Biotech, INC. | $221.45 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Lilly USA, LLC | $196.63 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $161.84 | 2021-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $132.49 | 2022-2025 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpi Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.